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intervening diseases at an earlier stage, 
and reducing healthcare expenditures by 
means of prediction and prevention of 
disease.[2] These wearable technologies 
include smartwatches, wristbands, hearing 
aids, electronic/optical tattoos, head-
mounted displays, subcutaneous sensors, 
electronic footwear, and electronic textiles 
(Figure 1a). They can be conformably 
placed on the epidermis, inserted through 
the skin or body orifices for measuring 
electrophysiological or biochemical sig-
nals, and delivering drugs.[3] Such tech-
nologies when incorporated in garments, 
accessories, or epidermal surface to pro-
vide electronic alerts, sense physical and 
biochemical information, or deliver drugs 
are broadly called medical wearables.[4,5]
Wearable devices have the potential to 
offer features such as augmented, virtual, 
and mixed reality, artificial intelligence, 
and pattern recognition.[6–8] These ubiq-
uitous computing technologies typically 
contain microprocessors, sensors, and 
smartphone interfaces including wireless 
data communications to record medical data in real-time and 
exchange information with other devices and/or centralized data-
bases.[9] Sensors integrated in wearable devices include inertial 
measurement units (gyroscopes, accelerometers, barometers, 
magnetometers), optical sensors (complementary metal–oxide–
semiconductor (CMOS) sensors, spectrophotometers, cameras, 
photoplethysmogram), chemical probes, electrodes, temperature 
Wearables as medical technologies are becoming an integral part of personal 
analytics, measuring physical status, recording physiological parameters, or 
informing schedule for medication. These continuously evolving technology 
platforms do not only promise to help people pursue a healthier life style, but 
also provide continuous medical data for actively tracking metabolic status, 
diagnosis, and treatment. Advances in the miniaturization of flexible elec-
tronics, electrochemical biosensors, microfluidics, and artificial intelligence 
algorithms have led to wearable devices that can generate real-time medical 
data within the Internet of things. These flexible devices can be configured 
to make conformal contact with epidermal, ocular, intracochlear, and dental 
interfaces to collect biochemical or electrophysiological signals. This article 
discusses consumer trends in wearable electronics, commercial and emerging 
devices, and fabrication methods. It also reviews real-time monitoring of vital 
signs using biosensors, stimuli-responsive materials for drug delivery, and 
closed-loop theranostic systems. It covers future challenges in augmented, 
virtual, and mixed reality, communication modes, energy management, 
displays, conformity, and data safety. The development of patient-oriented 
wearable technologies and their incorporation in randomized clinical trials will 
facilitate the design of safe and effective approaches.
Personalized Medicine
1. The Rise of Personalized Medicine
The “quantified self” movement is the driving force behind 
wearable technologies involving acquisition of data on daily 
activities, sport performance, and health status.[1] In combina-
tion with value-based healthcare systems through telehealth, 
wearable devices can enable monitoring at risk patients, 
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sensors, microphones, shock detectors, strain gauges, and pres-
sure sensors.[10] Multiple arrays of sensors enable obtaining data 
from multiple wearable devices and routing to a body area net-
work.[11] This body area network can transmit the medical data 
to the Internet through Bluetooth, Wi-Fi LTE, 3G, 4G, or 5G 
connection for further analyses or feedback from a healthcare 
provider (Figure 1b). The capability of wearable devices, smart-
phones, and wireless communication devices to interoperate in a 
network infrastructure of connected devices constitutes Internet 
of things (IoT).[12] Within this scheme, the medical data can be 
acted upon within the network or sent to emergency services, 
medical databases or physician’s office to obtain therapeutic feed-
back about the health status.[13] The diagnostic information col-
lected from a sensor or an array of sensors can be connected, for 
example, to a drug delivery system to administer a precise dosage 
of a medication, or an assistive technology for impaired mobility.
1.1. Sensory Information in Wearables
Wearable devices integrated with electronic and optical biosen-
sors can provide real-time data about the electrophysiological 
or biochemical status of a patient at point-of-care settings or 
in the clinic. Such biosensors can be embedded in electronic 
tattoos/stamps, patches, prosthetics, textiles, wristbands, and 
contact lenses to form conformal contact with biological tissue 
or bodily fluids. These biosensors may be wirelessly powered or 
run via lightweight batteries that can be seamlessly integrated 
in wearable devices. Physical and biochemical data can be 
wirelessly transmitted to the patient or another wearable device 
for achieving closed-loop therapeutic systems.
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Figure 1. Wearables devices for medical applications. a) Wearable devices (in vitro) have loose or conformal contact with the skin, or worn/inserted 
through body orifices. The most common interface is loose skin contact wearables, which measure electrophysiological signal via optics and electrodes. 
b) Information transfer from wearables. The data collected from wearable devices can be transmitted to the Internet or other devices via a body area 
network, Bluetooth, Wi-Fi, LTE, 3G, 4G, or 5G connection. The medical data can be sent to a healthcare provider to receive therapeutic feedback or 
acted upon automatically by other devices in the network.
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1.1.1. Close-Contact Wearables
Conformable mounting of a wearable device on the human 
skin requires compatibility between the mechanical properties 
of the compliant wearable device substrate and the stiff surface. 
Understanding the mechanophysiology at the interface of the 
wearable device and epidermis is critical in wearable device 
design, which should adhere to strict design guidelines for 
the selection of materials and the geometry of the patterns to 
prevent device failure. The surface of the skin consists of fea-
tures having 10–1000 µm height and it can be assumed to be 
a bilayer structure: the epidermis (thickness = 0.05–1.50 mm, 
Young’s modulus = 140–600 kPa) and the dermis (thickness = 
0.3–3.0 mm, Young’s modulus = 2–80 kPa).[14] This skin bilayer 
is linearly elastic for tensile strain values < 15% and enters 
plastic deformation above 30%. Hence, the mechanical prop-
erties of the device materials such as Young’s modulus and 
bending stiffness must be compatible with the mechanical 
properties of the skin. Elastomers having low Young’s mod-
ulus (50–100 kPa) are preferred in the fabrication of wearable 
devices. If the device contains standard electronic components 
having silicon (160 GPa) or gallium arsenide (90 GPa), the 
effective moduli can be within the range of 100–150 kPa.[15] 
Wearable devices may have a bending stiffness within the 
range of 1–10 nN m. Low effective moduli and thin devices are 
ideal to prevent interfacial cracks and interface delamination 
from the skin. The effective modulus of a close-contact wear-
able device can be calculated by approximating the substrate, 
sensing units, and interconnects. The effective modulus can be 
approximated as Eeff = Econnect (1 + LdLs−1), where Econnect is the 
effective modulus of the interconnects, Ld is the characteristic 
wearable device size, and Ls is the distance between sensing 
units or components.[15] These devices maybe mounted to the 
skin using a polyvinyl alcohol film support (thickness = 50 µm, 
Young’s modulus ≈1.9 GPa).
Tattoo-like films and patches placed over the skin have been 
utilized as temperature, electrophysiological, and strain sen-
sors (Figure 2a).[15] Electrical components were constructed 
on a ≈30 µm gas permeable silicone sheet having low Young’s 
modulus (≈60 kPa) similar to that of the human skin. The 
elements of the electronic tattoo consisted of conventional 
semiconductor materials including silicon, gallium arsenide, 
which were patterned as serpentine ribbons in microscale 
geometries. The wearable device was elastic under strain 
deformations having effective moduli of less than 150 kPa 
and bending stiffness of 1 nN m, thus allowing for it to be 
mounted on the skin via a temporary support polyvinyl 
alcohol film. Surface tension forces facilitated the adhesion of 
the wearable device to the skin having 20% areal contact of 
electronic components with the skin to establish an electrical 
interface. These tattoos could incorporate different compo-
nents including capacitors, light-emitting diodes (LEDs), tran-
sistors, radio frequency inductors, photodetectors, rectifying 
diodes, and oscillators. Moreover, electronic tattoo electrocar-
diograms (ECG) distinguished phases of heartbeats such as 
depolarization of the cardiac wave, and associated QRS waves 
in an ECG. Other uses of electronic tattoos are noninvasive 
electromyogram recording on the throat for recognized vocali-
zation of different words.[15]
Wearable piezoelectric tattoos have been fabricated to 
measure soft tissue viscoelasticity over epidermis (Figure 2b).[16] 
A device was constructed from stretchable networks of mechan-
ical actuators, and nanoribbon sensors containing lead zirconate 
titanate. The device incorporated capacitor-type components 
including various piezoelectric layers, which were fabricated 
on elastomers (20 µm) to achieve stretchable mechanics. Lami-
nation of the wearable piezoelectric actuator–sensor devices 
allowed for forming conformal contact with soft biological tis-
sues via van der Waals forces, where the bending stiffness per 
sensor width was 4.5 × 10−8 N m. Cycles of stretching over 
1000 times showed no delamination of the sensors from the 
substrate. Measurements of the localized skin properties over 
lesion sites showed higher modulus (≈6 mPa) than normal skin 
regions (≈5 mPa) in patients. The wearable device shaped as a 
protractor allowed quantitatively measuring viscoelastic moduli 
with spatial mapping for potential applications in the derma-
tological examination of basal ganglia carcinoma, fibroepithe-
lial polyp, and histiocytoma.[16] In another study, conformal 
epidermal sensors were designed for strain detection.[17] The 
sensor consisted of LC resonators with capacitive electrodes 
that responded to variation in skin mechanics. Changes in the 
LC resonance frequencies were detected by monitoring the 
absorption of the coil electromagnetic energy, which was linked 
to an impedance detection device. The device had a resolution 
of 1.3% in strain detection. This sensor may allow monitoring 
the mechanical properties of the skin (e.g., lymphedema).[17]
Commercial integrated circuits and hardware can be incor-
porated in flexible polymer layers. Interconnected assemblies of 
chips have been created by microfluidic suspension in silicone 
elastomeric enclosures.[18] In this assembly, each component 
was attached to the bottom surface of the enclosure through 
localized support posts. The electronic components were 
suspended in a surrounding dielectric fluid to isolate them 
mechanically. These components were joint to each other via 
serpentine-shaped interconnects. The constructed system had 
the capability of acquisition, filtering, low-noise amplification, 
and frequency-modulated RF transmission of electrophysi-
ological data. The resulting assembly could be stretched (≈30% 
uniaxial strain) and twisted (≈75%). The final device was lami-
nated over the skin to create a sensory interface. Lamination 
of the device over the sternum enabled wireless collection of 
ECG (≈2.4 GHz) at distances up to 1 m. Q, R, and S waveforms 
were identified with low signal-to-noise values as compared to 
the commercial hardware.[18]
A wearable drug-delivery device featuring silicon nanomem-
brane strain sensors, a temperature sensor, a resistive random 
access memory (RAM) array, and electroresistive heaters has 
been developed (Figure 2c).[19] The RAM was formed by depos-
iting TiO2 membranes within interstitial gold nanoparticle 
layers assembled via Langmuir–Blodgett process. A key concept 
of this wearable technology was energy-efficient RAM due to 
the incorporation of gold nanoparticles to extend usage time. 
The constructed RAM operated at 100 µA, where the data was 
readable over 100 operations. The RAM did not have signifi-
cant signal drift post 1000 stretching cycles at ≈30% strain. The 
sensors were used to monitor the tension and compression 
cycles on a wrist for potential application in detecting tremor 
frequencies in Parkinson’s disease and epilepsy.[19] The device 
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was able to log data in different memory cells in every 10 s and 
the data was read in every 0.5 s. The capability to store data was 
used to trigger and control drug release. The drug delivery unit 
was created by forming m-silica nanoparticles loaded with ther-
apeutic compounds on a polymeric hydrocolloid membrane. 
An electroresistive heating unit was utilized to transdermally 
deliver drugs as well as serving as a temperature sensor. As 
the heat increased in the wearable device, the physical bonding 
between the nanoparticles and the drug degraded to diffuse the 
drug transdermally.[19] This demonstrated wearable device was 
not wireless; hence, the integration of built-in microprocessors, 
wireless communication, and energy transfer/storage units will 
lead to practical feedback-based wearable devices.
Tattoo-based wearables integrating optical sensors have been 
utilized as indicators for UV radiation exposure. Solar radia-
tion is a risk factor for the major skin cancer forms including 
cutaneous melanoma and carcinomas (basal and squamous 
cells).[20] Hence, the development of wearable sensors is 
highly desirable for determining the amount of UV exposure 
to develop awareness about the application of sun screens. La 
Roche-Posay (L’Oreal) has recently commercialized a water-
resistant stretchable skin sensor to monitor UV exposure to the 
skin.[21] Under the UV exposure, the photosensitive dyes within 
the 100 µm thick patch change color, which can be read with a 
smartphone camera.[22] The patch is air-permeable and can be 
worn up to 3 d.
A wearable tattoo-based sensor was developed to monitor 
alcohol in sweat.[23] The device had an iontophoretic-biosensor 
along with a flexible electronics unit. Wearables could be a con-
venient technology to monitor alcohol intake to prevent unsafe 
drinking. Alcohol consumption results in 3.3 million deaths 
globally,[24] and in the United States, ≈25 000 people die each 
year due to drunk driving.[25] This device uses sweat secreted 
by the transdermal delivery of the pilocarpine via iontophoresis. 
Ethanol was amperometrically measured using a Prussian Blue 
electrode transducer comprising alcohol oxidase enzyme. The 
Figure 2. Applications of wearable devices. a) Electronic tattoos conformally attached to the skin via van der Waals forces. Reproduced with permis-
sion.[15] Copyright 2011, American Association for the Advancement of Science. b) A compliant modulus sensor comprising nanoribbons of lead 
zirconate titanate in arrays of mechanical actuators and sensors. The upper and lower insets show the interconnected array and actuator/sensing 
regions. Reproduced with permission.[16] Copyright 2015, Nature Publishing Group. c) A wearable device that can monitor muscle activity, store data, 
and wirelessly communicate data closed-loop therapy. The inset shows a wearable RAM array (10 × 10) on the patch. Reproduced with permission.[19] 
Copyright 2014, Nature Publishing Group. d) A wearable wristband consisting of electrochemical sensors for the quantification of concentrations 
of glucose, lactate, electrolytes (Na+, K+ ions), and temperature for application in real-time perspiration analysis. Reproduced with permission.[28] 
Copyright 2016, Nature Publishing Group. e) Prosthetic skin featuring pressure, strain, humidity and temperature sensors, as well as electroresistive 
heaters for creating a skin-like perception. The inset shows the prosthetic skin under ≈20% strain. Reproduced with permission.[32] Copyright 2014, 
Nature Publishing Group. f) A antimicrobial peptide-functionalized graphene sensor on a tooth for wireless detection of bacteria. Reproduced with 
permission.[47] Copyright 2012, Nature Publishing Group.
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sensor detected blood alcohol concentration within the range 
of 0.001–0.062%. However, variation in skin permeability and 
sweat composition limits the practical use of this wearable 
device. Moreover, a startup company (BACtrack) has designed 
a wearable sensor that measures the blood alcohol content 
(BAC) from sweat.[26] A lag time of ≈45 min was recorded for 
the alcohol to be present in sweat; hence, this wearable device 
measures a person’s recent history of drinking habits. Another 
wearable device that can track alcohol is PROOF, which utilizes 
an enzymatic electrochemical sensor to measure perspired 
alcohol concentration.[27] The cartridge of the sensor can be 
used for continuous measurements of alcohol over 12 h.
Noninvasively monitoring a patient’s health status at the 
molecular level is the key in advancing the applications of wear-
ables. A wearable device that can be worn on wrists or arms has 
been developed for application in wireless perspiration analysis 
(Figure 2d).[28] The device comprised of multiplexed electro-
chemical sensors on a flexible circuit board for quantitatively 
monitoring electrolytes and metabolites in sweat. To realize 
the device, signal transduction, signal amplification, calibra-
tion, and wireless data transfer have been integrated within one 
chip. Glucose and lactate oxidase were immobilized within a 
chitosan substrate and Ag/AgCl conductor was used as refer-
ence counter electrodes. Amperometric detection was used as 
sensing units within a chitosan film. Prussian blue was used 
as a mediator to decrease the reduction potentials and activated 
the sensors without an external power source. Electrolytes were 
measured with ion-selective electrochemical electrodes, where 
poly(3,4-ethylenedioxythiophene)–poly(styrenesulfonate) per-
formed as an ion-to-electron transducer, and CNTs were incor-
porated within the polyvinyl butyral reference membrane for 
continuous measurements.[29] Furthermore, a microcontroller 
embedded in the wearable device calibrated and compensated 
the signal drift of the sensors. The data was communicated to 
a handheld device via on-board wireless transceiver and Blue-
tooth connection. The concentrations of monovalent metal ions 
(Na+ and K+) as well as glucose and lactate were continuously 
monitored in a human subject while exercising with a constant 
load. Although the sweat concentrations of glucose, K+ ions and 
lactate decreased during exercise, sweat Na+ ion concentration 
increased.[28] These changes might be attributed to the dilution 
of analyte concentrations. The wearable device was also utilized 
to determine dehydration status of a group of subjects during a 
prolonged outdoor running trial. Recently, a wearable patch that 
integrates biochemical analysis and electrophysiological sig-
nals has been fabricated.[30] By incorporating a three-electrode 
amperometric biosensor and a bipolar electrocardiogram sensor 
on a flexible polyester sheet, real-time measurements of lactate 
and heart function was achieved. The wearable patch trans-
ferred the monitored signals to a mobile device by Bluetooth 
low-energy. Additionally, epidermal patches that can measure 
pH have been developed for application in the assessment of 
the wound healing.[31] Mesoporous microparticles have been 
functionalized with pH-sensitive dyes. The electrostatic interac-
tions between the mesoporous structure and the pH-sensitive 
dye prevented dye leakage. These particles have been loaded to 
alginate microfibers via a microfluidic spinning system. The 
microfibers created conformal contact with the skin and they 
were able to measure pH within the range of 5.5–7.5.
Challenges exist in the material selection to maintain the 
conformal contact with the skin. For example, dead cell efflux 
through the skin may interfere with the measurement data. 
Another challenge that limits the adoption of electronic tattoos 
is that long time-wear over the skin may cause ‘irritant’ derma-
titis. One potential direction in the development of electronic 
tattoos is the use of surgical-grade stainless steel and its alloys 
that can provide high hypoallergenic features.
1.1.2. Wearables over the Body
The development of electronic prosthetics can allow for sensor-
laden bionic systems having spatiotemporal resolution. An elec-
tronic prosthetic skin has been created to incorporate single 
crystalline silicon nanoribbon pressure, strain, temperature, 
humidity sensors, and electroresistive heating units for nerve 
stimulation (Figure 2e).[32] The sensors were organized in iso-
lated layers and the device mechanically coupled on curvilinear 
surfaces. This three-layer artificial skin had localized perception 
in response to external stimuli to act as a peripheral nervous 
system interface. The bottom layer of the electronic skin had 
electroresistive filamentary heating units on a polydimethylsi-
loxane (PDMS) substrate. The middle layer had temperature, 
pressure, and strain sensors organized in linear and serpentine 
patterns. The top layer contained a humidity sensor array com-
prising coplanar capacitors. Each layer had interconnections 
to an external microprocessor. The capability of the device to 
function as a prosthetic skin was tested in different scenarios. 
For example, the prosthetic skin can map spatiotemporal 
strain, detect temperature changes (0–65 °C), and measure the 
humidity level of an object. Additionally, the signals from the 
prosthetic skin were transmitted to the corresponding periph-
eral nervous system in a rat model. To create a skin-nerve 
interface, multielectrode arrays were coated with platinum 
nanowires, where ceria nanoparticles were adsorbed to scavenge 
reactive oxygen species to potentially prevent inflammation. 
Electrophysiological signals originating from the ventral pos-
terolateral nucleus revealed that the pressure sensor response 
resulted in synchronized spikes, showing electrical signal trans-
mission to the central nervous system.[32] A limitation of this 
system includes the entrance of fractured platinum nanopar-
ticles into the bloodstream and the role of ceria nanoparticles 
in the inflammation suppression was unclear. Recently, tactile 
pressure sensors have been developed in the form of active-
matrix arrays consisting of pressure-sensitive graphene transis-
tors with air–dielectric layers.[33] These tactile sensors allowed 
detecting a broad pressure range from 250 Pa to 3 MPa.
1.1.3. Textile-Based Wearables
Sensors have been incorporated into fabrics to create textile-
based diagnostic devices. The electrodes were sawn into tex-
tiles using a computerized embroidery machine in customized 
geometries.[34] These embroidered electrochemical sensors 
have been used for quantitative analysis in biofluids. Glu-
cose and lactate oxidase were immobilized on conductive Ag/
AgCl-coated treads to create these flexible sensors on textiles. 
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As the concentration of glucose was increased from zero to 
40 mmol L−1 in blood, the current through the embroidered 
electrodes shifted 0.9 mA.[34] Additionally, lactate oxidase elec-
trodes that underwent 100 cycles of bending (90°) showed 
negligible difference in the sensor readouts. In another study, 
polyurethane-based ion-selective membranes were integrated 
with textile-based potentiometric sensors to create stretchable 
diagnostic devices.[35] The polyurethane membrane and carbon 
nanotube (CNT) ink was combined with a platinum-catalyzed 
silicone film having Ag/AgCl ink and a reference electrode 
for the quantification Na+ and K+ ions. A wireless high-input 
impedance voltmeter was used to transfer real-time measure-
ment data to a tablet computer with an iOS application. Na+ 
and K+ ion selective electrodes showed a limit of detection of 
≈10−5 m.[35] Other sensors integrated within textiles have been 
utilized for physiological monitoring such as respiration,[36] 
heart rate,[37] and temperature measurements.[38]
1.1.4. Electronic Footwear
The analysis of human walking patterns is required to cor-
rect abnormal gaits. An electronic shoe-based gait monitoring 
device has been developed to monitor patients with walking 
problems.[39] To measure ground contact forces, continuous 
pressure transducers were utilized with a fuzzy logic algorithm. 
This algorithm allows the detection of abnormal foot pressure 
patterns that do not follow natural sequence of gait phases. In 
another study, electronic shoes have been designed to monitor 
human motion and body posture.[40] A mobile 3D motion cap-
ture in combination with inertial sensors and electronic shoes 
was devised to enable diagnosis and analysis of abnormal pos-
tures. The measurements of ground reaction forces obtained 
from the electronic shoes are converted to quaternion in order 
to prevent gimbal lock. These electronic devices can be con-
figured to harvest energy to power a Bluetooth step counter 
system.[41] Such a system may consist of a magnetoinductive 
transducer for power conditioning to utilize the energy recovery 
as the shoe impacted on the ground. The energy harvester in 
the shoe involved exploiting pulse width modulation for per-
forming transducer output ratification and emulating optimal 
load impedance and charging a storage capacitor. In a typical 
foot step, the mean energy recovery was 644 µJ. In another 
study, electronic shoes have been utilized to assess the walking 
ability of elderly patients with lumbar spinal stenosis.[42] The 
electronic shoes had an array of sensors to measure lateral 
plantar pressure, heel-strike, and toe pressure with spatiotem-
poral resolution. These sensors acquired real-time data at 80 Hz 
and transmitted this information to a computer via the IEEE 
802.15.4 standard. The Oswestry disability index was estimated 
in a 10 min self-paced walking test and machine learning algo-
rithms were employed.
Electronic socks have also been developed to monitor vital 
functions in the body. In one such study, piezoresistive pres-
sure sensors were knitted in a sock to wirelessly measure 
gate and plantar pressure up to 500 kPa.[43] The data allowed 
evaluating running and walking modes of asymptomatic and 
flat foot. In another study, electronic socks were utilized to pre-
vent pressure-induced foot ulcers in diabetic patients.[44] The 
socks consisted of cotton, polyamide, silver-coated cotton, and 
piezoresistive fibers. Silver-coated fibers knitted to piezoresis-
tive fibers collected and transmitted an electrical signal, which 
was correlated with pressure values. The real-time data was 
stored in a centralized serial memory and sent to a computer 
wirelessly via Bluetooth. In another study, foot motion was 
monitored with electronic socks comprising flexible conduc-
tive polymers on an elastic textile.[45] When the socks were sub-
ject to strain, the resistance of the conductive polymers were 
changed. These sensors were utilized to measure foot motion 
patterns at joint locations. Dynamic input strain was tracked 
up to 4 Hz. The sensors allowed distinguishing motion around 
metatarsophalangeal and ankle joints during dorsiflexion. 
Recently, an electronic shoe consisting of textile sensors con-
nected to a low energy local area Bluetooth beacon has been 
used to improve athletic performance by optimizing the bio-
mechanics of running.[46]
1.1.5. In Vivo Interface Wearables
Wearable electronic films have been incorporated over the 
surface of tooth enamel (Figure 2f).[47] A graphene layer was 
printed onto water soluble silk allowing for self-assembly of 
antimicrobial peptides for bacteria detection in saliva. The 
device also featured a resonant coil for wireless detection 
of H. pylori, which causes 90% of stomach cancers and duo-
denal ulcers.[48] The wireless query operation was achieved by 
a parallel resonant circuit having a gold-coated meander line 
inductor as well as capacitive electrodes. The resistance change 
was wirelessly monitored as a function of the concentration of 
bacteria present in saliva. The in vitro studies showed a correla-
tion between bacteria concentration logarithm and variation in 
resistance showing a detection limit of ≈100 cells.[47]
Ocular diagnostic devices have undergone rapid develop-
ment over the last decade.[49] Intraocular pressure can be 
monitored though measuring the forces acting on the contact 
lenses to manage glaucoma. To measure intraocular pressure, 
capacitive,[50] piezo-resistive,[51] mechanical strain gauge,[52] and 
microinductor[53] sensors have been developed. Sensimed AG 
has introduced a contact lens sensor (Triggerfish) that holds 
Class IIa CE approval.[54] The sensor comprised Pt–Ti strain 
gauges for measuring the dimensional changes over corneo-
scleral junction for estimating intraocular pressure. An external 
wearable device attached to the waist of the patient wirelessly 
powered the Triggerfish contact lens while it received wireless 
readouts. This contact lens sensor provided readouts up to 288 
measurements within 24 h. However, wearing Triggerfish con-
tact lenses produces physiological irregularities as compared to 
conventional contact lenses, resulting in low oxygen transmis-
sibility to the cornea and altering intraocular pressure measure-
ments.[55] Another limitation of Triggerfish is that the readouts 
are in arbitrary units, hence the clinical interpretation of the 
results are challenging.[56]
The prospect to use contact lenses to quantify tear fluid 
composition through smartphones or a wearable device has 
generated interest from Verily, Microsoft, and Novartis.[49] Blood 
and tear fluid have a compositional difference due to the blood–
tear barrier; however, the concentrations of analytes in both 
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fluids have a relationship as a result of plasma leakage.[57] Their 
correlation allows using tears as a surrogate for the continuous 
measurements of blood chemistry.[58] Contact lenses have been 
functionalized with electronics and photonic crystals to report 
on the concentrations of analytes in tear fluid.[59] Detection 
approaches including electrochemical, fluorescence, and pho-
tonic crystal probes have been integrated in contact lenses for 
the continuous monitoring of analytes in tears. Miniaturized 
electrochemical sensors featuring 3-electrode systems were 
coupled with enzymatic reactions for the quantitative measure-
ments in contact lenses.[60] Such contact lens sensors could be 
powered by near-field inductive coupling.[61] An electrochemical 
sensor incorporating glucose oxidase enzyme was tested in rab-
bits.[62] The contact lens sensor tracked the tear fluid glucose 
concentration ((0.03–5.00) × 10−3 m), which had a 10 min delay 
time depending on blood glucose. The utilization of gold elec-
trodes featuring 3D pillars increased the surface area (300%) 
as compared to 2D geometries to achieve a sensitivity of 40 × 
10−6 m in vivo.[63] Electronic contact lenses may be configured to 
provide quantitative or semiquantitative readouts wirelessly or 
using an LED display. For example, based on the concentration 
of the glucose, the intensity of an LED embedded in the contact 
lens can change, where the light output can be quantified using 
a smartphone camera. Similarly, for semiquantitative applica-
tions, for example, when the glucose concentration in tears 
decreases below 0.9 mmol L−1 (threshold value), and the LED in 
the contact lens can be turned on or off.[64] Other electrochem-
ical sensors embedded in contact lenses were utilized to quan-
tify lactate concentration in 35 s with 53 µA mm−1 resolution.[65]
Optical sensors including fluorescence probes have been 
also investigated. Glucose concentration in tear fluid was 
measured by hydrogel-coated nanospheres comprising tetra-
methylrhodamine isothiocyanate concanavalin A and fluo-
rescein isothiocyanate dextran in contact lenses.[66] These 
fluorescence probes allowed monitoring tear glucose concen-
tration in a diabetic human patient over 3 h. A photofluor-
ometer via a telemetry transmitter was utilized to send the 
readouts to an insulin pump.[67] Additionally, crystalline col-
loidal arrays and holographic sensors have been incorporated 
into contact lenses to continuously sense glucose using phe-
nylboronic acid derivatives in hydrogels.[68] These sensors can 
be fabricated by exposing a photosensitized hydrogel matrix 
to laser light interference in Denisyuk holography mode, or 
self-assembly of highly charged monodispersed spheres that 
form close-packed crystalline arrays in hydrogels via electro-
static repulsion.[69] Phenylboronic acids form reversible cova-
lent bonds with glucose molecules.[70] As the concentration of 
the glucose increases, the phenylboronic acid functionalized 
hydrogel swells due to Donnan osmotic pressure changes.[71] 
Hence, changes in the hydrogel volume results in diffracted 
Bragg peak shifts, which can be used as an optical trans-
ducer to report on glucose concentration in tears.[72] These 
reversible optical sensors can quantify a wide range of ana-
lytes including pH,[73] metal ions,[74] carbohydrates,[75] and 
alcohol,[76] as well as temperature.[77] Such photonic devices 
may be also printed in 2.5D format on flexible substrates to 
sense humidity and glycerol.[78] Bioinspired optical nanostruc-
tures may be also incorporated in contact lenses for applica-
tion in real-time sensing.[79]
Microfluidic contact lenses have been fabricated by laser 
ablation and fiber templating. A microlithography method 
has been developed to create microconcavities and microchan-
nels in contact lenses.[80] The microfluidic channel diameters 
ranged from 100 to 150 µm and their stability properties were 
evaluated by flow testing of artificial fluid. Microfluidic contact 
lenses were also functionalized with fluorophores to demon-
strate their optical emission capabilities in the visible spec-
trum. Microfluidic contact lenses may allow sampling tear fluid 
for multiplexed sensing in vivo and they may simultaneously 
deliver drugs to the eye.[80]
The capability to monitor glucose concentration in interstitial 
fluid as a surrogate for blood chemistry allows preventing hypo-
glycemic episodes and tightly controlling the glucose concentra-
tion throughout the day.[81] Real-time monitoring of glucose in 
conjunction with automated insulin pumps lowers the glycated 
hemoglobin (HbA1c) level, which is an indicator for glycemic 
control.[82] Continuous glucose monitoring systems utilize min-
imally invasive subcutaneous sensors to measure glucose con-
centration in interstitial fluid via electrochemistry.[83] Such glu-
cose sensors can communicate with insulin pumps to create a 
closed-loop feedback to control the concentration of the glucose 
in blood (normal: 4.2–6.4 mmol L−1, diabetics: >7.0 mmol L−1). 
Commercial continuous glucose monitoring systems include 
Guardian REAL-Time (Medtronic), SEVEN Plus/G4 (Dexcom), 
FreeStyle Navigator (Abbott), HG1-c (C8 Medisensors), and 
GlucoTrackT (GlucoTrack). The electrochemical sensor probes 
(length = 9–14 mm) are subcutaneously inserted into the inter-
stitial fluid at 45° from skin normal. Recently, new interfaces 
and connectivity options have been introduced to continuous 
glucose monitoring systems. For example, G5 Mobile CGM 
System (Dexcom) offers real-time glucose monitoring that can 
be monitored through a smartphone, tablet computer, or smart-
watch via Bluetooth. The smartphone application sends audio 
alerts to the patient when the concentration of the glucose in 
interstitial fluid is low or high. The information can also be 
displayed on Apple Watch and Fitbit smartwatch. The develop-
ment of smartwatch applications triggered open-source projects 
(e.g., NightScout movement), in which patients develop their 
own medical applications to access their continuous glucose 
measurement data using AndroidWear.[84] The readout data can 
be monitored by others or shared with healthcare professionals. 
Apple health kit, for example, was developed in response to 
these requirements of connecting devices for gathering medical 
data in a secure environment, and under complete transpar-
ency for healthcare professionals and regulatory authorities; 
and used in wearable glucose monitoring trials.[85]
1.2. Limitations in Existing Sensing Technologies
Electrochemical sensors degrade in vivo due to biofouling, 
which requires replacement every 3–4 d.[86] These electrochem-
ical sensors, typically used for the management of diabetes, are 
intrinsically prone to drift in vivo; hence they require frequent 
calibration with finger prick blood tests. The measurement of 
glucose concentration in interstitial fluid is associated with 
a lag time as compared to blood glucose. Limitations of these 
wearable glucose sensors apply to all types of electrochemical 
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sensors and include (i) frequent calibration of the sensor, (ii) 
sensor readout drift due to biofouling, (iii) biweekly sensor 
replacement, and (iv) relatively high cost. Other well-known 
sensors in wearables include heart rate monitors, thermom-
eters, and accelerometers. These types of sensors have been 
fully characterized and work seamlessly; however, the amount 
of signal processing and data processing required to for health-
care applications is large and requires continuous operation 
and energy supply.
1.3. Next Generation Sensors
Power-efficient sensors are increasingly gaining significance 
in wearables. Recently, a low-power temperature sensor was 
developed based on complementary temperature dependencies 
of n- and p-type metal-oxide-semiconductor field effect transis-
tors in the subthreshold region.[87] Tunneling currents and a 
capacitive charging-time-to-digital feedback allowed digitizing 
the temperature at 113 pW, operating from 10 to 60 °C.[87] Such 
individual sensors can be interconnected within wearable body 
area networks.[88]
Transient technology is an emerging field and it refers to 
a group of devices that dissolve over a period of operation.[89] 
This may allow practical disposability properties at point-of-care 
settings. After the exposure of the transient device to a stim-
ulus, the functionality of the device is controllably terminated 
in a specific period of time. The applications of these transient 
devices have been realized in bioelectronics, environmental 
monitoring, and energy harvesting. The transient behavior of 
such devices can be initiated primarily by aqueous solutions, 
but also at a lesser extent with light, temperature, or mechan-
ical forces. The main substrate building blocks may consist of 
water-soluble polymers such as polyvinylpyrrolidone (PVP), 
poly(vinyl alcohol), polylactic acid, polylacticcoglycolic acid 
(PLGA), and polycaprolactone (PCL). In transient electronic 
devices, magnesium (Mg), zinc (Zn), iron (Fe), tungsten (W), 
and molybdenum (Mo) have been explored as degradable con-
ductive materials. Recently, a transient material based pseudo-
CMOS was demonstrated.[90] The 800 nm thin device con-
sisted of a degradable cellulose substrate and iron electrodes 
with thermal and chemical stability to achieve and operating 
voltage of 4 V (Figure 3a). In a recent study, transient materials 
have been developed for pH and electrophysiological sensing 
(Figure 3b,c).[91] A capacitive electrophysiological sensor was 
connected to a preamplifier having low-input capacitance and 
high-input impedance. Near-unity gain was achieved in the 
preamplifier enabling electrophysiological measurements via a 
SiO2 insulation layer. The amplifier and filter units of this tran-
sient device provided tunable gain from 60 to 80 dB for elec-
trocardiogram and electromyogram measurements, where the 
results were comparable to conventional gel-based electrodes.
A biodegradable electronic patch integrated with flexible 
heaters was developed to deliver drugs on demand.[92] This ther-
mally-controllable patch allowed administering antibiotics. A 
blend of poly(glycerol sebacate)-PCL was synthesized and elec-
trospun to create elastic sheets (tensile modulus = 4–8 MPa), 
where the fiber diameters ranged from 350 to 1100 nm. A 
metallic heater was deposited on the elastic sheet, which 
released antibiotics upon thermal stimulation. In vitro studies 
showed that the patch successfully released cefazolin in agar 
plates inoculated with Staphylococcus aureus and E. coli. Wound 
patches (1.5 cm in diameter) having heaters resulted in a zone 
of inhibition up to 1.0 cm over 24 h as compared to control 
samples without a heater.[92]
2. Utilization of Wearables Sensory Data
2.1. Management of Wearables Data
2.1.1. Data Storage and Communication
Commercial solid-state, nonvolatile flash memories are based 
on rigid silicon data storage units. In this scheme, the data 
is first converted into a charge level and stored in floating 
gates.[93] Recent advances in the memory development focused 
on improving flexibility and stretchability, which are required in 
medical wearables. Flexible NOR type resistive random-access 
memories having one transistor–one memristor (1T–1M) struc-
ture have been developed.[94] These memory cells were created 
by integrating single crystal silicon transistors with an amor-
phous α-TiO2 memristor on a flexible substrate. Word, bit, and 
source lines allowed interconnecting the 1T–1M RRAM unit 
cells in the 8 × 8 NOR-type array to achieve independent cell 
control. Microcontact printing has been utilized to fabricate a 
flash memory based on a high-density Ag nanoparticle charge 
trapping layer on a flexible polyethylene terephthalate (PET) 
substrate.[95] A close-packed Ag nanoparticle monolayer was 
embedded at the interface of a blocking layer (200 nm) and a 
10 nm atomic layer-deposited Al2O3 (tunneling layer) to fabri-
cate a data storage unit controlled by external gate bias. As com-
pared to memory devices featuring a floating gate, a memory 
window of 16.5 V and retention time of 105 s was achieved. 
The produced devices had high-density storage sites and low 
lateral change leakage, as well as offering high endurance over 
1000 cycles and robust mechanical stability over 500 bending 
cycles.[95] Another study involved the development of flexible 
transistor organic memory devices consisting of (spin-coated) 
crosslinked PVP films and organic pentacene thin-film tran-
sistors (TFTs) on flexible matrices, in which Au NPs were uti-
lized as charge trapping elements.[96] The produced TFT-based 
nonvolatile floating gate device had a memory windows of 10 V 
and sustained operation over 1000 bending cycles times. Such 
organic memories can also be fabricated from polyimide (PI) 
and 6-phenyl-C61 butyric acid methyl ester (PCBM) on flexible 
PET substrates (Figure 4a).[97] Furthermore, flexible all organic 
vertically-stacked 64-bit memory cell arrays consisting of one 
diode-one resistor system without crosstalk have been devel-
oped (Figure 4b).[98] The memories components comprised of 
poly(3-hexylthiophene) (P3HT) diodes and a combination of 
polystyrene (PS) and PCBM on polyethylene naphthalate (PEN) 
substrates. A photocrosslinker (bis-perfluorobenzoazide:bis-
FB-N3) was utilized to covalently bind the P3HT and PS side 
chains by nitrene-based N-H insertion. The memory cell arrays 
were stable (ION/IOFF ratio ≈103) and had retention time of 104 s, 
displaying an endurance cycle of 102.[98] In a recent study, 
stretchable silicon nanomembranes circuits incorporate silicon 
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Figure 3. Transient electronics. a) Disintegrable electronics comprising iron as electrodes at various stages of disintegration in a pH 4.6 buffer solution 
(scale bars = 5 mm). Reproduced with permission.[90] Copyright 2017, United States National Academy of Sciences. b) A biodegradable pH sensor 
based on doped silicon nanoribbons (Si NRs) at different stages of dissolution while submerged in PBS (pH 10) at 24 °C. Reproduced with permis-
sion.[91] Copyright 2015, United States National Academy of Sciences. c) Capacitive biodegradable electrophysiological sensors and their dissolution 
in PBS (pH 10) at 24 °C. Reproduced with permission.[91] Copyright 2015, United States National Academy of Sciences.
Figure 4. Advances in flexible data storage and memory units. a) Photograph of a flexible 8 × 8 array-type Ti/Au/Al/PI:PCBM/Al organic memory device. 
Reproduced with permission.[97] Copyright 2010, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. b) A flexible 1D-1R organic resistive memory cell 
array on a flexible PEN substrate. Scale bar = 5 mm. Reproduced with permission.[98] Copyright 2013, Nature Publishing Group. c) Photograph of a 22 × 
22 multiplexed charge trap floating gate memory array (top) and a magnified image (bottom) illustrating four memory pixels interconnected with 
word and bit lines. Reproduced with permission.[99] Copyright 2016, American Association for the Advancement of Science.
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nonvolatile memory arrays with nanocrystal floating gates in 
a wearable device (Figure 4c).[99] Other emerging data storage 
technologies include piezoelectricity and inverse magnetostric-
tion.[100] These nonvolatile memories operate at low energy 
schemes with storage densities up to 0.2 µm2. Recently, ferro-
electric based nonvolatile flip flop memories (1.6 µs for 10-year 
data retention, and 170 ns for 10 h data retention) were devel-
oped to reduce power dissipation for heart rate data storage.[101]
Standard communication protocols for electronic devices 
include Bluetooth classic,[102] Zigbee,[103] and Wi-Fi.[104] How-
ever, these protocols have not been designed to be power-
efficient. Hence, early wearable device designs included pro-
prietary protocols to reduce energy consumption, but this 
approach restricted the use of interoperability in a personal-
ized network area or IoT.[105] To address these issues, Blue-
tooth low energy (BLE) was developed to achieve power effi-
ciency for short-range communication while operating within 
industrial, scientific, and medical (ISM) radio band (2.4 GHz) 
with a bandwidth of 1 Mbps.[106] This protocol allows transfer-
ring state information in small blocks of data at regular inter-
vals, where the processor operates in a low power mode.[107] 
It also supports Adaptive Frequency Hopping with a 32-bit 
cyclic redundancy check,[108] and the beaconing (advertising 
mode) in the BLE standard allows short, unsolicited messages 
at flexible update rates.[109] Thus, it provides a low power 
high-rate always connected transfer of data. Always-connected 
devices such as smartphones and IoT networks can serve 
as hosts for BLE-enabled wearables.[110] A recent advance in 
such enabling technologies is Bluetooth 5, which offers quad-
ruple data communication range with increased transmission 
power, and double the data speed (2 Mbps) as compared to 
Bluetooth 4.x.[111]
Body area wireless networks are currently being standard-
ized.[112] For example, the “400 MHz” band comprising Medical 
Implant Communication Serive band and ISM band are stand-
ardized under IEEE 802.15.6 for close-to-body wearables, also 
for low-power system-on-chip architectures.[113] An emerging 
problem with sensor networks is the interference with existing 
Wi-Fi systems that require more power.[114] Standards such as 
IEEE 802.11ah on other bands are adopted for “DeepSleep” 
power saving mode and energy harvesting.[115] BLE, ZigBee, 
the standard 2.4 GHz personal area network radios will still 
be used for independent sensor connectivity with healthcare 
platforms and the IoT.[116] Such interconnected sensors will 
require safety measures to protect the personal information 
and patient data.
Wearable devices need to be able to function with an inde-
pendent operating system offering low power consumption 
and user friendliness without being paired to smartphones. 
Android Wear 2.0 (Google) features new functions such as 
Google Fit and enhanced Google assistant, as well as Android 
pay via NFC and Smart Reply.[117] For example, Samsung Gear 
S offers a micro SIM card option, run applications, and able 
connect to Wi-Fi; however, it is only compatible with Sam-
sung smartphones.[118] In combination with upcoming 5G 
connectivity, that could enable laptops or IoT devices as con-
necting hubs, power-efficient medical wearables could access 
these connected nodes inside homes, clinics, or transportation 
systems.[119]
2.1.2. Data Processing and Interpretation
Real-time data acquisition in wearables requires continuous 
processor operation, which demands power consumption and 
thus low power domain sensors. Node processors for sensor 
signal acquisition offer low power consumption and energy 
management.[120] Fine-grained power management can be 
achieved via clock gating, which eliminates switches in the pro-
cessor to improve power efficiency.[121] Having multiple CPUs 
for different applications or parts of the feature-OS together 
with processors with low leakage can provide power-efficient 
wearable devices.[122] Within such systems, low internal clock 
speeds and input/output signal processes can be minimized to 
reduce the overall power consumption. Chip architectures are 
also being designed to operate at power down modes and adapt 
high-speed logic.[123] For example, Snapdragon Wear 1200 is a 
low-power, global navigation satellite system-enabled processor 
(Qualcomm) that supports LTE Cat-M1 (eMTC) and NB-1 (NB-
IoT) for application in wearables.[124]
2.1.3. Data Safety
The protection of the personal information and patient data in 
wearables is a significant concern. The ownership of the data 
from wearable devices is debatable. Currently some wearable 
device service providers limit their users’ access the access to 
the collected and stored data. These service providers charge 
their users’ fees to access their row data, which is also acquired 
by third-party companies. These third party companies also sell 
patient information (age, sex, height, weight, location, contact 
details) and global positioning-tracked activities.[125] While some 
manufacturers claim to anonymize patient data by removing 
identifying features, these protective approaches are inadequate 
to prevent identity fraud. Advanced algorithms have the capa-
bility of crossreference biometric information collected with 
wearable devices based on users’ behavior (activity time, loca-
tion) to reveal the patient’s identity.[126] For example, digital 
traces of patient information can be collected by social media to 
predict identity.[127] Furthermore, wearable device can be hacked 
by accessing the communication channel between the wearable 
device and smartphones.[128] Such security vulnerabilities have 
been previously observed in pacemakers and glucose pumps.[129]
Wearable device manufacturers and IT infrastructure should 
protect medically relevant data by providing tamper protec-
tion, authentication, data encryption, or end-to-end data integ-
rity. Tamper-resistant authentication protocols should be light-
weight to be integrated into wearables.[130] Digital cryptography 
requires computing power and is not available in wearable 
device applications. Physical cryptography offers an alternative 
strategy by using physical unclonable functions.[130] Moreover, 
authentication protocols can be extended to multiple party 
interactions, for example, user-device, device-network, and 
user-network systems.[131] Body signals may also be used to 
authenticate and create secure communications.[132] Addition-
ally, lightweight on-chip loadable data encryption protocols have 
been designed for wearable devices.[133] Preservation of data 
integrity from end-to-end user can be compromised by multiple 
encryption methodologies that can cause data loss.[134]
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2.2. Aided Living and Treatment with Wearables
Wearable devices have application in aiding patients with dis-
abilities and metabolic disorders. These applications range from 
aiding hearing to drug delivery. Wearables can be configured to 
deliver drugs through skin, eye, or ear interfaces. Their simple 
formats can actuate the release of therapeutics via mechanical 
stress or strain. These so called passive wearable devices consist 
of drug reservoirs directly embedded in the polymer matrixes 
or microneedle depots. When contacted with the body surface, 
drugs can be delivered by means of passive diffusion or elec-
tronic actuation. Such mechanisms can be triggered by heating, 
pH, or other chemical means to actuate a drug-impregnated 
medium or mechanically opening the depots to initiate drug dif-
fusion. These wearable devices can be integrated with biosensors 
to create closed-loop systems, in which the drug dosage can be 
controlled and wirelessly communicated to the user, and further 
connected to body area networks for tracking and monitoring.
2.2.1. Aided Living
Hearing impairment is the major reason of disability among 
old patients.[135] One of the early examples of the use of wear-
able devices in medicine was to treat hearing loss. Electroa-
coustic devices amplify sound and conformably fit behind 
auricle and/or in the ear canal for the correction of impaired 
hearing. These devices amplify quiet sounds audible, but a 
threshold mechanism prevents the amplifica-
tion of loud sounds. Such devices consist of 
an earmold, which may contain an electronic 
circuit, a microphone, a loudspeaker, and 
a battery (zinc–air, 1.35–1.45 V). However, 
recent miniaturized models offer devices that 
can be inserted in the outer ear bowl or the 
ear canal. Hearing aids can be wirelessly con-
nected to smartphones or tablet computers 
to directly tune the volume or the bass of the 
sound.[136] These wireless hearing aids can 
communicate with one another to adjust the 
audio properties simultaneous. Such devices 
offer FM listening devices with wireless 
microphones that can be used by a partner. 
These devices are examples of how wearables 
can interconnect. Additionally, these devices 
can connect to the mobile phones, audio 
sources, and TV streamliners via Bluetooth 
(2.4 GHz).[137]
2.2.2. Drug Delivery
Therapeutic agents can be released from 
wearable elastomer films by applying 
mechanical forces. A wearable device con-
taining a microgel depot has been developed 
to release drug loaded nanoparticles based 
on tensile strain triggering of an elastomer 
membrane (Figure 5a).[138] When tensile 
strain was applied to the elastomer film, the drug was released 
due to the Poisson’s ratio-induced compression of the microgel 
depot and the enlarged diffusion surface area. The wearable 
device could be configured to release antineoplastic and anti-
bacterial agents based on routine body motions, or pulsatile 
release by patient-controlled administration. The effectiveness 
of the doxorubicin-eluting film was demonstrated by inhib-
iting tumor spheroid, showing two times more reduction in 
tumor size as compared to passive drug release. Furthermore, 
ciprofloxacin was incorporated into the elastomer film treating 
local infection on a finger joint. The amount of ciprofloxacin 
released after 100 and 1000 finger movements was 9.2 and 
56.6 µg mL−1. Additionally, crosslinked hyaluronic acid micro-
needles were integrated within the wearable device to trans-
dermally deliver insulin to control the concentration of blood 
glucose in type 1 diabetic mice. After 10 cycles of stretching at a 
strain of 50%, the concentration of the blood glucose, which was 
at a hyperglycemic state (550 mg dL−1), decreased to the normal 
glycemic state (<200 mg dL−1) within 30 min.[138] To refill this 
drug delivery system, the microgel depot layer may be replaced 
while retaining the microneedles in situ.
Engineering biocompatible and flexible microneedles will 
minimize the risks of immune reaction and breakage after 
skin penetration. Microneedles made of high Young’s modulus 
materials such as silicon, nickel lack biocompatibility. How-
ever, microneedles created from polymers have low mechanical 
strength limiting their application in drug-eluting patches. 
The microneedles could be configured to dissolve in vivo. For 
Figure 5. Applications of wearable devices in drug delivery. a) Stretch-actuated drug delivery 
from elastomer films comprising microgel depots containing therapeutic nanoparticles for dia-
betes, anticancer, and antibacterial treatments. The device comprises a microneedle array (SEM 
image) for stretch-mediated control of insulin delivery. Reproduced with permission.[138] Copy-
right 2015, The American Chemical Society. b) A microfluidic reciprocating pump and electro-
magnetic actuators for intracochlear drug delivery. Reproduced with permission.[148] Copyright 
2016, The Royal Society of Chemistry. c) Latanoprost-eluting contact lenses on the surface of a 
rabbit’s eye for glaucoma treatment. The arrowhead illustrates the lens edge and the arrow show 
inner diameter of drug-polymer film. Reproduced with permission.[149] Copyright 2014, Elsevier.
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example, microneedles have been utilized to deliver influenza 
virus vaccine and dissolve in the skin within minutes.[139] 
Recently, a wearable patch comprising a bendable microneedle 
array was developed.[140] Each microneedle consisted of four 
bendable PDMS pillar bases and a rigid SU-8 or maltose sharp 
tip. The array tolerated the deformation associated with buck-
ling and lateral movement forces during skin penetration and 
daily wear without needle breakage. The concentration of blood 
glucose in rats treated with the insulin-eluting microneedle 
array decreased from over 5.5 h, where the dose was controlled 
from 50 to 183 µL by varying the pressing force.[140] This drug 
delivery system was integrated with a refillable microflu-
idic drug reservoir that was assembled at the backside of the 
microneedle patch.
A microneedle-based immunopatch has been created for 
melanin-mediated cancer treatment.[141] Polymeric micro-
needles consisted of B16F10 whole tumor lysate containing 
melanin. The microneedles released lysate upon insertion into 
the skin in a controlled manner. Excitation of the melanin with 
near-infrared light increased the local temperature that pro-
moted tumor-antigen uptake by dendritic cells to improved 
antitumor vaccination. This patch provided spatiotemporal 
immunotherapy that enhanced infiltration of polarized T cells 
and local cytokine release. Studies in mice showed increase in 
survival after tumor challenge targeting established primary 
tumors as well as distant tumors.[141]
Transdermal drug delivery has been achieved through ion-
tophoresis in graphene-based wearable devices.[142] A thermally 
controlled transfer printing approach has been developed to 
produce patterned graphene layers on an elastic stamp. Gra-
phene-based iontophoresis electrodes was used a heating unit 
(22–44 °C) to actuate the thermal transdermal drug delivery. 
Iontophoresis electrodes were laminated on the skin of a nude 
mouse and doxorubicin was loaded on the graphene electrodes 
and electric field was applied. The penetration of the depth 
of doxorubicin was proportional to the applied heat to gra-
phene and the concentration of iontophoresis stimuli.[142] Such 
wearable devices may also consist of nanofibers that can be 
designed in stretchable formats.[143] These devices many reach 
sheet resistance of ≈1.3 Ω sq−1 having a power efficiency of 
0.65 W cm−2 and an optical transmittance of ≈90%.
A textile dressing has been developed for temporal and 
dosage-controlled drug delivery.[144] The wound dressing con-
sisted of composite fibers having a core electrical heater, which 
was coated with an alginate (Alg)/poly(ethylene glycol) dia-
crylate (PEGDA) film to deliver a drug. The wound dressing 
allows releasing antibiotics and vascular endothelial growth fac-
tors (VEGF) to reduce bacterial infection and induce angiogen-
esis in vivo. To construct the fibers, a cotton thread was coated 
with a carbon ink. For example, a conductive tread having a 
diameter of 1.2 mm showed 5 Ω cm−1. The temperature of the 
fibers could be controlled between 25 and 45 °C as the applied 
voltage was increased up to 4.5 V. p(NIPAM/PEGDA) hybrid 
particles containing cefazolin and vancomycin have been syn-
thesized. For example, a 5 cm long thread released 30 µg cefa-
zolin over an hour, whereas four threads released 130 µm cefa-
zolin. In a diabetic mouse model, fabricated fibers were used to 
deliver VEGF to skin wounds of the animals to evaluate wound 
healing rate. Threefold increase in the granulation of the tissue 
deposition across the wound bed was measured as compared 
to the control group without VEGF.[144] These textile dressings 
may be integrated with hydrogel optical fibers and photonic 
nanomaterials for photodynamic therapy.[145]
Microfluidic systems have been developed to deliver drugs 
to inner ear fluid.[146] A microfluidic device has been fabricated 
to infuse and withdraw sub-microliter drug solutions to and 
from inner ear fluid to achieve a liquid transfer with zero net 
volume.[147] The drug delivery system consisted of a polymer 
reciprocating pump and an electromagnetic actuator for appli-
cation in head-mounted wearables. The mass transport of the 
drug molecules to the cochlea was achieved through diffusion 
and mixing. The programmable pump created a reciprocating 
flow and a reservoir to control the drug concentration in the 
infused bolus. The efficacy of the drug delivery device was 
evaluated by delivering 6,7-dinitroquinoxaline-2,3-dione to the 
cochlea of guinea pigs. After the implantation of the cannula by 
the 24 kHz region at the cochlea base, auditory nerve compound 
action potentials were monitored. As the reciprocating pump 
drove the drug at 0.64–1.18 µL infuse-withdraw in 3–4 min 
intervals, compound action potential thresholds increased for 
1 h and returned to normal levels.[147] A recent iteration of the 
device included an embedded drug reservoir and all fluidic com-
ponents in the microfluidic architecture (Figure 5b).[148] This 
intracochlear drug delivery system operated at 6 s drug loading, 
16 s infusion, and 10 min idle stages, where the energy con-
sumption was 20.9 J. This device allowed for running 157 cycles 
on a 3.8 V 240 mAh power source corresponding to 27.3 h run 
time. This miniaturized system may also allow for replacing the 
drug reservoir cartridge for long-term use.
A contact lens has been created to deliver latanoprost to the 
eye for the treatment of glaucoma.[149] The contact lens for-
mulation consisted of latanoprost-PLGA films encapsulated 
by methafilcon, which is a co-polymer of poly(2-hydroxyethyl 
methacrylate) (pHEMA) and methacrylic acid. The contact lens 
(dry thickness = 300 µm, wet outer diameter = 15 mm, wet 
central aperture = 4 mm) was fabricated by a combination of 
spincoating, and UV-initiated free radical polymerization, and 
lathing the material into a curved geometry. The amount of the 
drug (89–178 µg) encapsulated in the contact lenses was con-
trolled by varying the concentration of the latanoprost during 
UV polymerization. The drug was released by an early burst 
followed by sustained release over a month. 50–90% of the 
drug amount was released in vitro over 3 d depending on the 
thickness of the contact lens. The efficacy of the drug-eluting 
contact lens in the treatment of glaucoma was assessed by in 
vivo studies in rabbit eyes (Figure 5c). The concentration of the 
latanoprost released from 3-d preconditioned contact lenses 
decreased from 100 to 10 ng mL−1 over 3 d, followed by a sus-
tained release over a month.[149] Recently, enzyme-cleavable 
contact lenses were developed.[150] These lenses comprised 
nanodiamonds that released timolol maleate in the presence 
of lysozyme for sustained glaucoma treatment. The nanodia-
monds were coated with polyethyleneimine and crosslinked 
with an enzyme-cleavable chitosan to encapsulate timolol 
maleate. The nanodiamond drug reservoirs were embedded 
in a pHEMA matrix and casted to obtain a contact lens. In 
the presence of lysozyme, the contact lenses released 9.41 µg 
timolol maleate over a day.[150] This approach allowed for wet 
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storage of the contact lenses prior to use. Additionally, cipro-
floxacin-eluting contact lenses inhibited S. aureus for extended 
zero-order release.[151] These antimicrobial PLGA-pHEMA 
contact lenses completely inhibited 105 S. aureus cells as the 
cumulative mass release of ciprofloxacin was 4.5 mg over 28 d. 
In another study, econazole-eluting PLGA-pHEMA contact 
lenses have been fabricated for the treatment of fungal ocular 
infections.[152] The antifungal drug-release kinetics of the con-
tact lenses was tested in an assay against Candida albicans. The 
contact lenses comprising 16 mg econazole killed 100% of the 
Candida (0.5–1.0 × 107 cells) over 8–10 d.
2.2.3. Behavior Therapy
With the emergence of optical headsets such as Google Glass 
2, Oculus Rift and Magic Leap, HoloLens for application in 
video games and entertainment, reality simulation platforms 
have also found use in medical research, diagnostics, and treat-
ment.[153] These simulated reality platforms provide imagi-
nary environment, sounds, vibrations, and other sensations 
to observe and interact with the imaginary surroundings and 
items.[7,154] They can facilitate the management of mental and 
anxiety disorders including autism, posttraumatic stress dis-
order (PTSD), persecutory delusions, and phobias.[155] Ena-
bling patients to evaluate these mental challenges in a virtual 
reality social environment can allow the management of safety-
seeking or anxiety behaviors. Other applications of reality simu-
lation programs include ocular treatment, rehabilitation, pain 
management, and surgical training.
Brain power system for autism is a customized head-
mounted display that provides personalized coaching experi-
ences via a gamified augmented-reality application incorpo-
rating artificial intelligence modes.[6] This application aids 
the patient to establish emotion recognition, eye contact, 
face-directed gaze, and behavioral self-regulation. The head-
mounted display integrating the brain power system was uti-
lized to coach two children with clinically diagnosed Autism 
spectrum disorder. 24 h postintervention, these patients dem-
onstrated decreased disorder symptoms based on the aberrant 
behavior checklist.[156] In another study, head-mount displays 
were utilized to automatically recognize facial expressions.[157] 
The headset behaviorally aided children with Autism spectrum 
disorder by providing real-time social cues and minimizing 
distractions. This system displayed facial expressions and records 
social responses including eye contact time and using an eye 
tracker. A trial involving 38 children with Autism spectrum dis-
order and typically developing children showed correct emotion 
recognition rates within the range of 85–95%. While significant 
real-time physiological and behavioral data can be collected 
from mentally ill patients, the connection between the data and 
the emotions of the patient is unclear to draw definite diagnosis 
conclusions. Hence, the interpretation of the results for action-
able treatment is a challenge. In another study, a randomized, 
double-blind, placebo-controlled study of virtual reality expo-
sure therapy was designed to treat PTSD due to military trauma 
in veterans (n = 156).[158] Virtual reality exposure therapy was 
introduced to patients in six sessions to decrease the PTSD 
symptoms in combination with psychiatric medications, 
d-cycloserine (50 mg) and alprazolam (0.25 mg), and compared 
to the placebo effect. The virtual reality therapy augmented in 
reducing PTSD symptoms, and these reduced symptoms were 
maintained at 3–12 months of treatment.[158]
In a recent study, clinically diagnosed patients with persecu-
tory delusions (n = 30) were enrolled to virtual reality cognitive 
therapy sessions in order to decrease in delusional conviction 
and real-world distress.[159] Virtual reality cognitive therapy 
reduced delusional conviction by 22% and real-world stress by 
19.6% as compared with virtual reality exposure group.[159] In 
another study, VR was also used in treating glossophobia (fear 
of public speaking) by exposing subjects to a VR public speaking 
scene over 5 weeks.[160] Questionnaires such as attitude toward 
public speaking and subjective units of disturbance, as well 
as heart rate monitoring showed significant improvements in 
public speaking fear as compared to a control group.
Virtual reality head-mounted displays were utilized to treat 
patients with amblyopia.[161] Human subjects (n = 17) with 
clinically-diagnosed anisometropic amblyopia were enrolled in 
a 8-session dichoptic game-based training program (diplopia, 
vivid vision), which was operated on a Oculus Rift OC DK2 
display. The game involved flying a spaceship through a rings 
system, where the simulated system was in a 3D dichoptic 
virtual reality setup (Figure 6a). The virtual vehicle was only 
observed with the dominant eye and all the objects in the game 
were seen with the amblyopic eye to force the brain to coop-
eratively use both eyes. After the treatment, the corrected visual 
acuity of the patients significantly improved from 0.58 ± 0.35 
(LogMAR) to 0.43 ± 0.38 (p < 0.01), while mean stereoacuity 
Figure 6. Applications of virtual reality in medicine. a) Dichoptic training game seen through a head-mounted optical display in virtual reality. The 
amblyopic eye views the left side of the image to fly the spaceship through the blue gates. Spaceship is only seen with the dominant eye (right side). 
Reproduced with permission.[161] Copyright 2017, Springer. b) The RAPAEL Smart Glove system tracks the posture and the motion of a user’s distal 
limb. Reproduced with permission.[138,162] Copyright 2016, BioMed Central Ltd. c) The use of head-mounted optical displays with virtual reality in a 
pediatric burn patient during motion exercises. Reproduced with permission.[163] Copyright 2014, Mary Ann Liebert, Inc.
www.advmat.dewww.advancedsciencenews.com
1706910 (14 of 26) © 2018 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, WeinheimAdv. Mater. 2018, 1706910
shifted from 263.3 to 176.7 of arc, showing potential for the 
treatment of sight disorders.[161]
The rehabilitation effects of VR therapy were demonstrated 
on the distal extremity function of stroke survivors (n = 46) in 
a single-blinded randomized controlled trial.[162] Patients were 
divided into two groups consisting of electronic glove group 
and conventional intervention group (control) to assess changes 
in health-related quality of life indicators. The electronic glove 
(RAPAEL, Neofect) provided feedback by tracking the posture 
and the motion of the user’s distal limb (Figure 6b). The glove 
incorporated inertial and bending sensors that measure 3D 
position of the distal limb and the degree of finger bending. 
It had the capability to recognize the forearm pronation, ulnar 
deviation, wrist movement, and finger flexion. The software 
application then displayed a virtual hand and objects in real 
time. Fugl–Meyer assessment scores, Purdue pegboard test, 
Jebsen–Taylor hand function test, and Stroke Impact Scale 
indicated improvements in the rehabilitation outcomes as com-
pared the control group.
VR reality has been utilized as a pain distraction technology 
for wound care and physical therapy procedures of burn 
patients, where pain medications are inadequate.[163] In a case 
study, Oculus Rift VR goggles were used to immerse the 3rd 
degree burn patient into a virtual environment during occu-
pational therapy (Figure 6c). The patient had one occupational 
therapy session (no VR) on day 1, a VR-supported occupational 
therapy session on day 2, followed by a final occupational 
therapy session with no VR on day 3. Subjective rating of pain 
intensity results decreased from severely painful to moderately 
painful when VR was employed. These results were consistent 
with functional magnetic resonance imaging studies that 
showed pain-related brain activity decrease during VR induced 
pain distraction.[164]
2.3. Limitations of Wearable Treatment Approaches
Challenges remain in the development of theranostic sys-
tems that enable closed-loop dynamics and respond correctly 
to physiological and pathological conditions. The main draw-
backs of these technologies for application in point-of-care set-
tings arise from the limited integration and miniaturization. 
Early approaches to treatment of disease by wearables lacked 
the patient improvement feedback; however, under professional 
supervision they proved effective, for example, to mitigate Par-
kinson’s disease.[165] Others have operated under the assumption 
that the function of the wearable is continuously required, this 
has proven to be effective for renal failure patients.[166] Issues 
with wearables for treatment include low biocompatibility, insuf-
ficient conformal contact, inefficient energy consumption, and 
short lifetime. These factors limit the development of automated 
systems that can sense physiological stimulus and respond with 
an accurate therapeutic dosage to create real closed-loop systems 
worn long-term.
2.4. Building the Next Generation Wearables
Several efforts have been made to solve the limitation of closed-
loop wearables, nevertheless, wearable technologies are still 
in development. As an example, a promising wearable device 
featuring a graphene layer doped with gold, and integrated 
with a serpentine layer of gold mesh for electrochemical moni-
toring of glucose in sweat was developed (Figure 7a).[167] The 
device consisted of a humidity detector, a heater and tempera-
ture sensor combined with polyvinyl pyrrolidone microneedles 
for thermally activated transcutaneous drug delivery. After the 
patch was laminated on the human skin, the device was acti-
vated upon sweat generation in ≈15 min. After reaching 80% 
relative humidity, the concentration of the glucose and pH was 
measured in sweat. The microneedles were coated with trideca-
noic acid having a transition temperature of 41 °C. As the sen-
sors detected hyperglycemia, the microneedles were thermally 
activated by melting the tridecanoic acid coating to release N,N-
dimethylimidodicarbonimidic diamide (Metformin). Experi-
ments on diabetic mice showed suppression of blood glucose 
concentration by the Metformin-eluting array as compared to 
the control group (P < 0.05).[167] However, this system was not 
suitable for long term delivery of Metformin as the microneedle 
system consisted of bioresorbable tridecanoic acid coating.
Another challenge is the design of energy efficient thera-
nostic wearable technologies, as the energy requirements tend 
to be higher as their diagnostic or therapeutic wearable counter-
parts, nevertheless several examples of energy efficient devices 
exist.[19] Recently, a wearable microfluidic bandage incor-
porating sensors and a drug delivery system was developed 
Figure 7. Closed-loop wearables. a) A wearable device for glucose monitoring and drug-delivery that can wirelessly communicates with smartphones 
via Bluetooth. Reproduced with permission.[167] Copyright 2016, Nature Publishing Group. b) A microfluidic bandage on the arm. The wearable device 
consists of a capacitive touch detector, a temperature sensor, and a drug delivery pump. Reproduced with permission.[168] Copyright 2014, Wiley-VCH 
Verlag GmbH & Co. KGaA, Weinheim.
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(Figure 7b).[168] This bandage featured sensors, a microfluidic 
drug delivery pump, a wireless signal transmittance unit, and 
a microelectoromechanical system on a flexible substrate. The 
sensing units were fabricated by screen and shadow mask 
printing techniques in combination with laser cutting. A wire-
less coil, a capacitive touch sensor, and a temperature sensor 
were fabricated by patterning silver ink, conductive poly(3,4-eth-
ylenedioxythiophene)–poly(styrenesulfonate) and a CNT mix-
ture. The drug delivery pump was created by forming PDMS 
patterns via soft lithography as a semisphere fluid reservoir 
(0.2 mL). The temperature sensor operated from 20 to 50 °C at 
a sensitivity of 0.61 °C and functioned at a curvature radius up 
to 3.6 mm. The threshold pressure to eject a fluid was 3.3 kPa at 
a rate of 35 nL kPa−1, where the bending radius up to 6 mm did 
not alter the reservoir volume.[168] The wearable device was used 
to measure the temperature changes on human arm over time; 
nevertheless, the drug delivery capability was not tested and the 
transistors were not integrated within the device, showing lim-
ited translation to potential clinical settings.
In creating closed-loop automated systems for disease moni-
toring and drug release, the use of sensitive polymers such as 
chitosan, poly(methacrylicacid), modified poly(acrylamide), sul-
fonated polystyrenes, and ethylenevinylacetate have enabled the 
development of systems that interact directly with the tissue 
microenvironment. These materials can release drugs and 
modify its physical chemistry based on sensing physiological 
responses such as temperature, pH, light, electric fields and 
ultrasound waves.[169] Nevertheless, challenges remain in accu-
rately controlling the release of the desired drug dosage based 
on the physiological needs; however studies so far have been 
limited to characterizing the response of the stimuli-responsive 
material. In pathological conditions, the response of materials 
can be modeled to adjust their release kinetics via the devel-
opment of several physicochemical formulations. Nevertheless, 
to develop materials for clinical applications, the development 
should move from stimuli-responsive materials to physiologi-
cally sensitive materials that act and deliver drug dosages based 
in organic needs. The ideal material would have to adapt to 
several circumstances and respond to them in a personalized 
manner, as most of the current materials present a nonflexible 
behavior difficult to modulate after its fabrication. This part 
is fundamental to translate closed-loop technologies from the 
laboratory to the clinic as pathological states are fast-evolving 
physiological treats that need personalized interventions.
Wearable devices require hardware and software to acquire 
real-time data from the user. The data retrieved from sensors 
are processed, analyzed, displayed, or interpreted to produce 
actionable information. Hence, hardware and software interac-
tions need to be optimized for each wearable device. An over-
arching system architecture can be created for wearables, from 
which particular applications can be derived. As wearables are 
not user interface centric, plug and play architectures can be 
conceived when programing or specific data input is required. 
The application scenarios in disease diagnosis and drug 
delivery are determining factors for sensor types and processor 
types in signal analysis and device architecture. Nevertheless, 
certain components are usually included in all wearable device 
configurations. The wearables system architecture require-
ments are driven not only by the continuous data acquisition, 
but also by the need for a seamless user experience. In health-
care applications, long-term wear is paramount, also contin-
uous communication to the user for self-monitoring, and data 
transfer to a health professional.[170] As a rule of thumb, system 
architecture requirements are: (i) long battery life or capability 
to wirelessly receive power in conjunction with low power con-
sumption, (ii) continuous synchronization within IoT or local 
networks, (iii) robust sensors with low signal-to-noise ratio, (iv) 
high-performance data processing, (v) secure or encrypted data 
transfer, (vii) conformability, comfortability, thin geometry, and 
(vi) amenable to mass manufacturing at low cost.
2.4.1. Sensor Signal Acquisition, Processing, and Artificial 
Intelligence Algorithms
A large number of sensors and sensor networks can be inte-
grated into wearable devices. Sensor signal acquisition and pro-
cessing are key design parameters in wearables. High-quality 
raw data is necessary to ensure reliable diagnostic information; 
the majority of wearables face low-quality raw data acquisition 
leading to erroneous health evaluation and diagnosis.[171] Data 
processing algorithms have significance in obtaining high-
quality data in multiplexed wearable sensors, where the energy 
expenditure, heart rate variability, electrodermal response rate, 
arterial fibrillation, seizure, and stress levels need to be moni-
tored simultaneously (e.g., elderly at high risk of heart disease). 
The first on-chip data processing necessary for reliable data 
collection is the identification and reduction of motion arti-
facts, for which various algorithms have been developed. For 
example, using data from a 3D accelerometer, such artifacts 
can be reduced in ECG measurement systems or pulse oxi-
metry.[172] These adaptive filter algorithms typically consist of 
least mean squares algorithms and variations of the same such 
as adaptive step-size, or recursive LMS.[173] The next layer algo-
rithms correspond to feature extraction for the determination 
of sensory parameters. Since some biological signals oscillate, 
it is common to retrieve time frequency domain algorithms or 
fast Fourier transforms.[174] Common feature extraction and 
classification in wearable devices include dimension reduction 
such as principal component analysis, Laplacian eigenmaps, 
and independent component analysis.[175] Hilbert and wavelet 
transforms can enhance noise reduction and extract time-inde-
pendent features.[176] Multiscale analysis algorithms have also 
been utilized for long-term feature collection and analysis.[177] 
Other techniques include forward–backward sequential search 
using multilayer preceptors and nearest neighbor classifiers, 
which are machine learning algorithms.[178] Full artificial intel-
ligence algorithms are expected to be applied for integral signal 
processing in medical wearable devices.
Key trends for the development of wearable devices are 
multiplexed sensors, continuous connectivity, low power con-
sumption, and novel material integrations. However, multi-
plexed sensing is challenging due to different material-body 
interfaces and probe positioning. Multiple interconnected 
sensors can be positioned on body areas of importance. Short-
range radio signals for sensor networks have been proposed 
to reduce power consumption and achieve continuous sensor 
communication.[179] Preinstalled algorithms in microcontrollers 
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can meet the requirements of multiplexed sensor systems. For 
example, sensor system-on-chip (Imec) devices are capable of 
measuring ECG, respiration by bioimpedance, 3D accelerom-
eter data, all with preloaded signal analysis algorithms.[180,181] 
Other examples of system-on-chips include monitoring of car-
diac rhythm,[182] energy expenditure,[180] and the onset of sei-
zures.[183] Such architectures have evolved to operate at low 
voltages, low power, and fully integrate into standard chip 
architectures.
2.4.2. Energy Storage and Charging
Flexible battery constructs and energy management systems 
are key design components in wearables.[184] High-energy den-
sity batteries designed for wearable devices should withstand 
bending, folding, and stretching while being amenable to min-
iaturization and easily integrated (e.g., weaving).[185] The flex-
ibility of wearable devices mainly depends on the mechanical 
properties of the electrodes.[186] A rechargeable Li-ion battery 
has been fabricated from low-modulus silicone elastomers as 
substrates, segmented active components, and interconnected 
structures.[187] The battery consisted of pouch cells of 100 photo-
lithographically patterned Al and Cu disks connected in parallel 
with molded pads of cathode and anode consisting of LiCoO2 
and Li4Ti5O12. A spacer was created in the system, where a gel 
electrolyte injected into this gap acted as a medium for ionic 
transport. This system was encapsulated in a polyamide layer 
and packaged in acryloxy perfluoropolyether elastomer. The 
battery had a stretchability of 300% with a capacity density 
of ≈1.1 mAh cm−2 (Figure 8a). A wireless charging system was 
designed with 1 mm spaced coils, where the received power by 
the receiving coil was 9.2 mW, showing a DC output of 3.0 V 
with an efficiency of 4.9%.[187] Recently, fiber-shaped Li-ion bat-
teries were fabricated from yarns made of multiwalled carbon 
nanotube/lithium oxide composite,[188] and Si-carbon nano-
tubes.[189] Furthermore, lithium polymer technology is the cur-
rent benchmark for commercial products; however, Zn–air and 
Li–air batteries may offer longer energy storage.[190] Zn–air bat-
teries require the diffusion of atmospheric oxygen into a porous 
carbon electrode and consist of zinc metal as an anode and air 
electrode as cathode, which is separated into catalytic activity 
layer, gas diffusion layer, and a separator.[191] Rechargeable Li–
air batteries are also promising candidates as their theoretical 
and practical specific energies can reach up to 12 000 and 
4000 Wh kg−1.[192] As these batteries use Li as anode and oxygen 
is sourced from air to function as a cathode, they requires air 
dehydration membranes.[193]
To achieve wireless power transfer in wearable devices, 
stretchable microfluidic devices have been fabricated.[194] Liq-
uids in microfluidic channels can deform without signifi-
cant hysteresis and flow without discontinuity upon bending 
(Figure 8b). The maximum power efficiency was ≈10% cor-
responding to receiving power of 0.47 W from a transmit-
ting power of 4.6 W. The resulting wireless energy transfer 
device has the capability to function after 1000 cycles of strain 
(25%).[194] In another study, conductive yarns of silver-coated 
copper wire and polyester filaments have also been modi-
fied to transfer wireless energy.[195] The silver-plated copper 
wire (40 µm) was wrapped around polyester yarn of 75 denier 
with 150 twists m−1 and the copper filament was then turned 
700 twists m−1. To construct the final yarn, three strands were 
piled together to create a yarn density of 547 denier with a 
diameter of 0.3 mm resulting in a resistance of 89 mΩ cm−1. 
The number of turns (50) to construct the coil was designed to 
have a resonant frequency of 6.78 or 13.56 MHz for operation 
in medical (ISM) band.[195] An average power transmission effi-
ciency of 45% was achieved. Highest transmission was achieved 
at 6.5 cm with no interference by the skin contact with the yarn.
2.4.3. Displays
The physical and geometrical optoelectronic design con-
strains in semiconductor wafers can be reduced by creating 
inorganic light emitting diode, display, and photodetector lay-
outs on flexible polymeric substrates.[196] One approach is to 
use sacrificial substrate to construct electronic circuitry. For 
example, epitaxial semiconductor layers were produced on 
GaAs wafers, vertically etched, and these layers were sepa-
rated from the wafer by etching the AlAs layer.[197] These 
produced layers were then transfer printed on a temporary 
substrate coated with a trilayer of epoxy-poly-
imide-poly(methylmethacrylate) (PMMA). 
After interconnections, structural bridges, 
and encapsulating layers were formed, the 
PMMA layer was dissolved and the system 
was transfer printed over an elastomeric 
sheet such as PDMS substrate. µILEDs 
were connected by serpentine-shaped rib-
bons that served as electrical intercon-
nects and structural bridges (Figure 9a). 
The applied strains to these devices before 
and after stretching in horizontal and diag-
onal directions could reach 48% and 46%, 
respectively. The device characteristics were 
stable after 100 000 cycles in the horizontal 
direction, and the area expansion could 
reach 85% without any structural failures 
(Figure 9b).[198] Additionally, wearable devices 
Figure 8. Flexible batteries and wires energy transfer for wearable devices. a) Photograph of a 
biaxially stretched (300%) battery with serpentine interconnects. The inset shows the electrode 
pads and interconnects of the battery. Scale bar = 2.0 mm. Reproduced with permission.[187] 
Copyright 2013, Nature Publishing Group. b) A flexible liquid alloy coil for wireless power 
transfer. Reproduced with permission.[194] Copyright 2015, Nature Publishing Group.
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should preferably incorporate deformable full-color displays for 
conformal integration on curved surfaces. Recently, a quantum 
dot based LED array was fabricated by intaglio transfer printing 
onto flexible and curved surfaces (Figure 9c).[199] This high-
resolution printing process involved creating intaglio trench 
and nanocrystal layers that were transfer printed on different 
substrates. Quantum dot layers were first deposited on a donor 
substrate and then lifted with a PDMS transfer stamp and 
contacted (<50 g cm−2) on the intaglio trench. The resulting 
red–green–blue LEDs had a resolution of 2460 pixels in−1. 
These LEDs showed an electroluminescence performance 
of 14 000 cd m−2 with 7 V, and operated over 1000 deforma-
tion tests.[199] Recently, origami-inspired bazel-lens transistor 
arrays have been fabricated to create stretchable and foldable 
electronics.[200] The substrates composed of metal films and 
nanowires connected with elastomeric PDMS joints. Wear-
able devices, however, are not screen-centric and alternatives 
are being proposed for user interfaces that rely on connectivity 
rather than immediate display of information.
2.4.4. Comfort and Conformity
High level integration on the chip ensures compact organization 
of all components for medical wearables. Advanced packaging 
of electronics requires novel device assembly and chip building 
methodologies such as stacked dies (3D integrated circuits), 
multichip packages, or full systems in package.[201] Second, 
wearables require a small footprint to seamlessly integrate with 
the user’s body or clothing as functionality affects the wearing 
comfort.[202] Finally, innovative materials are required, not only 
to enhance conformity but to ensure body-device interaction 
and achieve high-quality signal acquisition. Analog sensor-
device interfaces are key for optimal health assessment and the 
quality of signals being transmitted. As wearable devices evolve, 
new materials will be required for individual type of sensors 
(impedance, conductive, optical), reduce motion artifacts, con-
tact with dry electrodes, identification of physiological differ-
ences, and measurement at nonoptimal positions. For example, 
polymers have been utilized for biointegration and obtaining 
optimal contact in wearable devices.[203] Strain-gauge sensors 
featuring high-aspect-ratio Pt-coated polyurethane nanofibers 
have been developed to mimic the mechanical properties of the 
human skin.[204] Piezoelectric crystals, optical components, and 
hybrid interconnects have been proposed for microelectronic 
architectures.[205] Additionally, electronic components can bend 
and adapt to the wearer’s activity leading to fiber- and textile-
based wearable electronics and sensor components.[4,206] User 
experience with wearables has been poor due to the ad hoc 
design of user interfaces, requiring manual control.
3. Wearables Market
With the emergence of “quantified-self” movement, tech-
nology companies have motivated their customers to seek 
wearable products in social pull marketing strategies. Con-
sumer-driven demand for Apple Watch, Samsung Gear, and 
Fitbit Wristband in the wearables market has prompted mass 
public attention.[207] These wearable technologies aim to 
improve physical performance and form positive exercise and 
diet habits through digital persuasion. Such wearable devices 
may offer social influencing or gamification of the exercise 
through creating challenges as well as virtual rewards to 
improve physical performance.[208] Worldwide market of wear-
able device sales has reached 125 million units in 2016, indi-
cating a 55% increase as compared to 2015; and the sales are 
estimated to reach 237 million devices by 2020 (Figure 10a).[209] 
North America had the highest regional share of sales (41%) 
in 2016, followed by China (27%) and Europe (14%). In 2016, 
325 million connected devices were in use worldwide and the 
users are projected to reach 929 million by 2021 with a Com-
pound Annual Growth Rate (CAGR) of 23% (Figure 10b).[210] 
Embedded cellular connectivity in wearables will subtly 
increase from 3.3% in 2016 to 7.4% in 2021. Wristbands had 
the largest market segment of unregulated wearables (53%) 
in 2016, followed by basic watches market (23%), which is 
shifting to smartwatches market (17%) (Figure 10c).[211] The 
main market segment focus of these consumer products is 
within connected fitness and sports monitoring technologies 
for tracking of exercise performance metrics.[212] The cus-
tomer base of wearable devices is mainly below the age of 44, 
and the penetration into older age groups has been limited 
(Figure 10d). Today one in five individuals in the United States 
own a wearable device that are mainly activity trackers.[213] 
However, wristbands market is projected to decrease due to 
the customer base transition to smartwatches that will offer 
new sensors and wider applications.[211] Additionally, smart-
watches will see an increase in market penetration due to the 
advances in cellular connectivity. 5G communication will be 
Figure 9. Flexible displays for wearable devices. a) Photograph of flexible display having a 16 × 16 array of ILEDs on a sheet of plastic (PET) wrapped 
around a thumb. The inset shows the display around a cylindrical glass tube (radius ≈12 mm). Reproduced with permission.[194,197] Copyright 2009, 
American Association for the Advancement of Science. b) An image of an array of ILEDs array (6 × 6), stretched on the sharp tip of a pencil. Repro-
duced with permission.[198] Copyright 2010, Nature Publishing Group. c) A photograph of green QLEDs laminated on wrinkled Al foil. Reproduced with 
permission.[199] Copyright 2015, Nature Publishing Group.
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a crucial part of these wearable technology paradigm shift, 
in which customers will demand faster and secure data con-
nection through their wearable devices, smartphones, and tel-
ehealth.[214] Smart garments market is expected to grow due to 
the integration of electronics and traditional clothing industry 
to create textiles and connected apparels for application in fit-
ness, drug delivery, and clinical trials.[5,215]
In the regulated wearables market, insulin pumps dominate 
the market with a share of 54% in the United States in 2016 
(0.7–1.0 million pump users worldwide) (Figure 10e).[216] Blood 
pressure monitoring devices have the second largest regulated 
wearables market segment (19%), which can be attributed to the 
hypertensive patients, which correspond to 16–37% of popula-
tion globally.[217] Furthermore, chemical sensors are projected 
Figure 10. The wearables market. a) Unit sales worldwide by region. b) Number of connected wearable devices worldwide. c) Wearables forecast 
by product type worldwide. d) User penetration by age group. e) Regulated wearable devices by product category in the United States in 2016. 
f) Sensor type market projection of wearables market by 2020. g) Annual investment and the number of deals. h) Investment deal breakdown by stage 
(2013–2014). i) Revenues in wearables worldwide.
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to have 40% of the market share followed by the inertial meas-
urement sensors (20%) by 2020 (Figure 10f). This trend will be 
driven by the advances in the development of low-power micro-
electromechanical systems and biochemical continuous moni-
toring systems that do not require frequent calibrations.[218]
Over $3.7B has been invested in emerging startups in 
wearables since 2012 corresponding to an increase of 351% 
(Figure 10g).[219] The majority of investments were angel/seed 
(36%) and series A (36%) funding and more than two thirds 
of the deals were in this space largely driven by True Ventures, 
Andreesen Horowitz, Khosla Ventures, First Round Capital, 
Bessemer Venture Partners, and Intel Capital (Figure 10h).[220] 
Largest deals in 2016 included Magic Leap ($793M, series C), 
Jawbone ($165M, series F), Thalmic Labs ($120M, series B), Razer 
($75M, series C), and Chrono Therapeutics ($48M, series C). 
California has been dominant in the wearables space, repre-
senting 77% of the total funding and half of the companies 
were funded in this region. The sales have been mainly in 
North America and Europe as well as in China and the market 
is projected to grow in these regions. The wearables industry 
involving the device sales, software, and data services has gener-
ated $33B in 2016. A limited 10% growth is expected until 2018 
when the market would reach $40bn, followed by an accelerated 
growth of 23% through to over $100B by 2023 and, a slower 
growth (11%) to reach over $150B by 2025 (Figure 10i).[221]
4. Regulatory Pathway of Wearables
Wearable devices are regulated in the same way as any other 
medical device based on medical use intent. These regulations 
are in place to ensure that wearables do not harm patients 
during device use or result in the long-term effects. Wearable 
devices are associated with numerous risks to patients and their 
use in conjunction of regular software updates introduces an 
additional layer of risk factor and complexity. FDA has issued a 
guideline, entitled “Mobile Medical Applications Guidance for 
Industry and FDA Staff” in 2015 to clarify its stance and eval-
uate the intended use and functionality of wearable devices.[222] 
For example, if a wearable device monitors blood pressure of 
a patient with heart disease, it would fall under these regula-
tions. However, if a patient uses the wearable device to record 
his/her calories during his exercise, it will not be regulated. 
As another example, wearable devices providing electrocar-
diograph measurements must acquire physiological data and 
have a comparable performance with commercial electrocardi-
ography devices. FDA regulations do not distinguish between 
platforms or device size, but focuses on the medical function 
and intended use.[223] As the quantified-self movement rises 
rapidly, there is a genuine concern among regulatory bodies 
for the unintended use of wearables developed for exercise and 
entertainment purposes. For example, a patient may use an 
inaccurate exercise-focused calorie-counting wearable device to 
manage his/her diet that can lead to unintended health conse-
quences. Currently, most wearable devices in the market lack 
controlled experiments. The majority of the manufacturers 
have not published empirical data and accuracy values, as this 
may originate from large error values. Another significant issue 
is related to automated software updates, which may introduce 
bugs to the wearable devices. There is not only lack of evidence 
on the performance of the claims by some device manufac-
turers, but most of them rely on the approvals granted for the 
individual sensors. Controlled studies are required for per-
formance evaluation under clinical and point-of-care settings. 
Furthermore, the effects of electromagnetic waves on human 
health have been widely studied in smartphones. However, the 
electromagnetic effects of wearable devices having closer con-
tact to the body in a continuous manner have not been studied. 
Electromagnetic radiation may affect transitions between 
energy states of molecules including DNA and proteins, as well 
as disruption of the neuron firing.[223] Hence, the exposure of 
the continuous electromagnetic fields on tissues and biological 
mechanisms warrant further research.
5. Connecting Wearables to Clinics
The majority of commercial wearables are used by individuals 
who are healthy and seek methods to quantify their fitness pro-
gress.[224] However, potential medical applications of wearables 
are broader ranging from point-of-care diagnostics to treatment. 
Wearables have applications in home monitoring to evaluate 
disease progression, patient’s response to medication, or health 
recovery after surgical intervention. In the case of chronic dis-
eases, wearables have the advantage of logging patient data in 
real time. For example, the severity of depression can be meas-
ured by quantifying physical activity, conversation timelines, 
and sleep duration.[225] Furthermore, wearables can allow early 
diagnosis of sleep apnea, which can be treated by improving 
sleep quality.[226] The analysis of the body movements may allow 
diagnosing Parkinson’s disease at an early stage.[227] Wearables 
also have applications in the home monitoring of a wide range 
of long-term medical conditions via electronic self-reports, web-
based counseling, and e-mail feedbacks to facilitate positive 
behavior. These medical conditions may include post-traumatic 
stress disorder,[228] anxiety,[229] panic disorders,[230] obesity,[231] 
and asthma.[232] The key advantage of wearables is to provide 
instant feedback for each patient, replacing subjective question-
naires to obtain clinical data.
Real-time monitoring of vital signs may reduce the burden on 
hospital appointments, and FDA-cleared devices in the market 
are already used for this purpose. An actigraphy measurement 
device, having a triaxial accelerometer and a light intensity sensor 
to monitor luminous intensity has been used to monitor limb 
or body movements to assist specialists in diagnosing sleep dis-
orders.[233] It was successfully tested in measuring sleep quality 
and physical activity to assess dementia progression in older 
adults.[234] Another wrist-worn FDA-approved product is an elec-
tronic diary for collecting patient reported outcome. Obtaining 
subjective data is useful for ecological momentary assess-
ments,[235] but also to monitor appetite,[236] satiety,[237] pain inten-
sity,[238] analgesic use,[238] sleep onset and latency,[239] and phys-
ical activity.[240] Additionally, another FDA-cleared, wearable mul-
tiparameter vital sign monitoring device records and transmits 
electrocardiography (ECG), heart rate, respiratory inductance 
plethysmography, calorific expenditure, posture/activity, skin/
core temperature, and oxygen consumption.[241] Experimental 
studies to monitor physiological signals and ECG for detecting 
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arrhythmias have been successfully carried out using this type 
of technologies.[242] As compared to the standard laboratory 
equipment, the heart and respiratory rate values were clinically 
acceptable (95% limit of agreement) for application in ambula-
tory monitoring. There are ongoing clinical trials, for example, 
to monitor patients with amyotrophic lateral sclerosis,[243] and 
new wearables are entering commercialization such as electronic 
stamps (tattoos) to monitor temperature, heartrate, and glu-
cose.[244] Hence, wearables are creating new market segments for 
the real-time analysis of patient’s health status. Software com-
ponents are integral part of most wearable technologies, regu-
lations, and compliance of such products is paramount for the 
integration of wearables into the healthcare systems.[245]
6. Patient-Centered Wearables
A limited number of randomized and controlled studies has 
been carried out to measure the efficacy of wearable devices on 
consumer behavior and health. Evaluations of different wear-
able devices (e.g., fitness trackers) for monitoring physical 
activity showed inaccurate variations with error margins up to 
25%.[246] These error margins are comparable to those of mobile 
medical applications having failure rates up to 30%.[247] In a 
recent study, the ECG data of Fitbit fitness trackers (Surge and 
Charge HR) equipped with PurePulse technology were tested 
among 43 healthy adults.[248] Fitbit fitness trackers were off by 
≈20 beats per minute during medium/high-intensity exercise. 
Another study that evaluated the step counts recorded by Fitbit 
One indicated valid results at multiple running speeds on a 
treadmill; however, the measurement of distance travelled was 
inaccurate.[249] Similarly, commercial fitness trackers tend to 
overestimate the calories burnt by 30%, which puts the patients 
at risk who adjust their diets and exercise plans to maintain or 
lose weight.[250] Over-reliance on wearable devices in particular 
with patients with chronic, life-threatening conditions (e.g., 
diabetes) may result in false sense of security and misdiag-
nosis.[251] Additionally, the measurement of metabolic signals 
and their delivery in real-time to the patient does not neces-
sarily improve the outcomes. A randomized trial of self-tracking 
of blood glucose concentration in noninsulin treated type-2 dia-
betics showed no convincing improvement.[252] Another study 
in newly diagnosed type-2 diabetic patients indicated that self-
monitoring of glucose was associated with depression.[253]
While pedometers and smartphone applications have been 
shown to decrease blood pressure and body mass index, these 
interventions were not proven to achieve continued behavioral 
changes during the intervention.[254] Additionally, the person-
ality of the patient influences the efficacy and perceived per-
formance of the wearable device.[255] The short-term behavior 
change in the exercise activity of the patients can be attributed 
to the novelty effects.[256] One third of wearable users com-
pletely discontinue using their devices after six months.[257] 
Moreover, the quality of life indicators including cost-effec-
tiveness, mental and social functioning are rarely reported in 
mobile health monitoring studies, where the existing study 
criteria and methodologies need significant improvement.[258] 
While the advances in the development of wearable devices 
will undoubtedly grow in the upcoming decades, randomized 
clinical studies are needed to evaluate their real impact in 
patient care. In the near future, wearable devices not only will 
be preventive, diagnostic, and therapeutic technologies, but also 
will enable continuous acquisition of data to monitor disease 
progression, drug response and assess clinical trial efficacy.
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